HBK Investments’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
– Sell
-274,214
Closed -$6.46M – 1341
2018
Q3
$6.46M Sell
274,214
-206,386
-43% -$5.04M 0.05% 231
2018
Q2
$11.1M Buy
480,600
+326,582
+212% +$7.76M 0.07% 158
2018
Q1
$3.79M Buy
154,018
+140,018
+1,000% +$3.68M 0.03% 336
2017
Q4
$376K Buy
+14,000
New +$356K ﹤0.01% 808
2017
Q2
– Sell
-12,800
Closed -$219K – 988
2017
Q1
$219K Buy
+12,800
New +$223K ﹤0.01% 626
2016
Q4
– Sell
-340,238
Closed -$7.08M – 836
2016
Q3
$7.08M Buy
340,238
+284,658
+512% +$7.06M 0.06% 184
2016
Q2
$1.5M Buy
+55,580
New +$1.52M 0.01% 479
2015
Q3
– Sell
-115,400
Closed -$3.16M – 1091
2015
Q2
$3.16M Buy
+115,400
New +$3.24M 0.03% 304
2015
Q1
– Sell
-37,600
Closed -$796K – 1110
2014
Q4
$796K Buy
+37,600
New +$840K 0.01% 605
2013
Q3
– Sell
-146,000
Closed -$2.26M – 934
2013
Q2
$2.26M Buy
+146,000
New +$2.43M 0.04% 239

Other funds holding NVO

HBK Investments's NVO Position: Q4 2018 in Review

HBK Investments sold out of Novo Nordisk (NVO) in Q4 2018, closing a stake of 274,214 shares — an estimated $6.46M sold.

HBK Investments first reported a position in NVO in Q2 2013 and held it in 10 quarters. The position peaked at $11.1M in Q2 2018. 550 funds tracked by Wall St. Rank hold NVO as of Q4 2018.

  • HBK Investments reported no remaining Novo Nordisk position as of Q4 2018 after selling out during the quarter.
  • HBK Investments sold 274,214 Novo Nordisk shares in Q4 2018, an estimated $6.46M.
  • HBK Investments first reported a position in Novo Nordisk in Q2 2013 and held it in 10 quarters.
  • HBK Investments's Novo Nordisk position peaked at $11.1M in Q2 2018.
  • 550 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2018.

Based on HBK Investments's 13F filing for Q4 2018, filed 14 Feb 2019.